Aramis Biosciences Completes Enrollment of its Phase II Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease November 3, 2022 Read more
Aramis Biosciences Announces First Patient Dosed in Phase II Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease February 28, 2022 Read more
Aramis Biosciences Announces FDA Clearance of IND Application for A197, a Novel Immunomodulatory Agent for the Treatment of Dry Eye Disease January 11, 2022 Read more